steroids
Case‐Based Introduction to Steroid-Related Adrenal Issues
Case 1 – 10-year-old girl with severe persistent asthma
Co-morbid GERD → required Nissen fundoplication.
Controller therapy before crisis:
High-dose mometasone/formoterol 200/5\;\mu g\;\text{BID}
Omalizumab SQ.
Additional “yellow-zone” plan from Colorado team: budesonide/formoterol PRN (PURIM).
2018–early 2019: ≥2 oral steroid bursts (dexamethasone & prednisone taper).
Feb 2019 nocturnal episode: dyspnea, visual disturbance, HA, dizziness, clammy, diarrhea, palpitations → adult ER (initial low BP, resolved) then children’s ED.
Extensive work-up: CT head, CXR, EKG, MRI brain ± contrast, LP → unremarkable; ENDO labs clinched diagnosis:
AM cortisol < 1 µg/dL.
ACTH < 5 pg/mL (low despite expected HPA rebound → acute exogenous suppression).
ACTH stimulation test:
Baseline cortisol 1.2\;\mu g/dL
30 min 7\;\mu g/dL, 60 min 6\;\mu g/dL (expected ≥ 18\;\mu g/dL).
→ Dx: Secondary adrenal insufficiency (AI) from steroid therapy.
Treated with physiologic hydrocortisone; weaned off after several months; repeat stim normal → cleared.
2020: brief systemic steroids for pneumonia/asthma; AM cortisol acceptable; no further AI.
Clinical pearls from Case 1
AI can masquerade as vague malaise (“weak & dizzy all over”).
Bold/ more common symptoms: fatigue, dizziness, nausea/vomiting/diarrhea, abdominal pain, poor weight gain, arthralgias/myalgias, striae.
Emergent red flags: hypotension, hypoglycemia → adrenal crisis → \uparrow\;\text{mortality}.
Who Needs Screening for Adrenal Suppression?
Literature + CHOP pathway:
Any systemic glucocorticoid ≥ 2 weeks (peds) or ≥ 3 weeks (adults) → risk of HPA suppression.
Repeated or chronic bursts in the preceding 12 mo.
Cushingoid appearance.
Screening test of choice: fasting AM serum cortisol (draw by 08:00).
Kids:
\ge10\;\mu g/dL → normal.
<3\;\mu g/dL → almost always abnormal.
3–10\;\mu g/dL → grey zone.
Adults: “normal” threshold closer to 18\;\mu g/dL.
Consider simultaneous ACTH.
Abnormal/indeterminate → ACTH (